2018 CIMT ANNUAL REPORTMEMBERS MEETING VERSION

CIMT.EU MEETING.CIMT.EU ASSOCIATION FOR CANCER IMMUNOTHERAPY CIMT

ANNUAL REPORT 2018 MEMBERS MEETING VERSION

CIMT | Supporters 2018CIMT

32

The 16th CIMT Annual Meeting was made possible by the generous support from our sponsors and partners:

SUPPORTERS 2018ANNUAL MEETING

Platinum

Gold

Bronze

Silver

Partner

CIMT | 16th CIMT Annual Meeting CIMT | 16th CIMT Annual Meeting

54

16th CIMT Annual MeetingPushing frontiers in cancer immunotherapy

The 16th CIMT Annual Meeting covered a wide array of topics in which cancer immunotherapy research has continued to push the frontiers of understanding: from elucidating the mechanism of action behind a proven concept, to optimizing existing therapies with clever engineering, synergizing efficacy via combinatorial approaches, or examining the tumor environment as a whole.

Given the wealth of information in the understanding, development and regulation of cellular therapies, the scientific program featured three different sessions on this topic: cellular therapies in general, CAR T-cell therapies in particular, and the translational and regulatory aspects of CAR T-cell therapy. The meeting’s Keynote Lecture was delivered by Ronald Germain of the National Institute of Allergy and Infectious Diseases in Bethesda, USA, entitled “Highly multiplex 2D and 3D imaging of the immune system and tumors.” Dedicating his lecture to the principle that “seeing is believing”, Dr. Germain showed compelling and beautiful images generated from two-photon excitation-based intravital microscopy to address fundamental questions of how immune cells find each other and interact to effect immune responses in complex environments. Bristol-Myers Squibb generously sponsored an Immuno-Oncology 2018 and Beyond session, offering lectures on immunotherapy from a clinical perspective.

All this content was available to 750 participants featuring 28 plenary lectures and over 40 short talks over the three days of the meeting.

May 15-17, 2018

CIMT | 16th CIMT Annual Meeting CIMT | 16th CIMT Annual Meeting

76

Cellular TherapyAndrew Sewell Cardiff University Gwen Binder-Scholl AdaptimmuneRodabe Amaria University of Texas MD Anderson Cancer Center

Immuno-Oncology 2018 and Beyond (supported by Bristol-Meyers Squibb)Viktor Grünwald Medical School of Hannover Guy Ungerechts National Center for Tumor DiseasesAndreas Jung Ludwig-Maximilians-Universität Munich

Counteracting Immune EscapeTania Watts University of Toronto Melody Swartz University of ChicagoJan P. Böttcher Technical University Munich

Keynote LectureRonald Germain NIAD, NIH

Tumor MicroenvironmentAndrea van Elsas Aduro Biotech Falk Nimmerjahn University of Erlangen_NurembergVincenzo Bronte University of Verona

CAR T-cell Therapy (organized by CARAT)Bruce Levine University of Pennsylvania Martin Pule University College LondonPeter Borchmann University Hospital of Cologne

Combination TherapiesShannon Turley GenentechSandra Demaria Weill Cornell Medical CollegeJack Pollard Sanofi Oncology

ImmunoguidingGünter J. Hämmerling German Cancer Research Center DKFZ Dimitrios Mastellos National Center for Scientific Research ‘Demokritos’Nicholas McGranahan Cancer Research UK Lung Cancer Centre of Excellence

Plenary speakers of the 2018 Annual Meeting Scientific Program

Regulatory Research (organized by CIMT-RRG and CARAT)Martina Schüßler-Lenz European Medicines Agency Bernd Schröder Miltenyi BiotechMartin Hildebrandt Technical University Munich

Therapeutic VaccinationJolanda de Vries Radboud University Özlem Türeci German Cluster for Individualized ImmuneIntervention (Ci3)Yared Hailemichael MD Anderson Cancer Center

Meeting reports Beck, J., Birtel, M., Reidenbach, D., Salomon, N. and Diken, M. CIMT 2018: Pushing frontiers in cancer immunotherapy — Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines & Immunotherapeutics. 2018. DOI: 10.1080/21645515.2018.1504526

CIMT | 2018 Travel AwardsCIMT | 2018 Poster Award Winners

98

2018 Poster Award Winners

Christof Smith – University of North Carolina at Chapel Hill “Pan-cancer analysis of human endogenous retrovirus expression reveals markers for prognosis and immunotherapy response in clear cell renal carcinoma”

Adam Grippin – University of Florida“Bifunctional RNA-nanoparticles to enhance dendritic cell activation and enable MRI-based detection of dendritic cell migration to lymph nodes”

Daniel Baumann – German Cancer Research Center DKFZ“Mouse models of pancreatic cancer for development of combinatorial immunotherapies involving cytostatic agents and agonist anti-CD40 antibody”

Jonas Bochem – University Medical Center Tübingen“Peripheral blood NKT-cell frequencies and their PD-1 expression levels identify stage IV melanoma patients with poor overall survival under PD-1/CTLA-4 blockade”

Julien Schmidt – University of Lausanne“TCR-pMHC 2D affinity and bond lifetime under force correlate with tumor-specific CD8 T cell responsiveness“

Chloe Chong – Ludwig Center for Cancer Research“Mass spectrometry-based antigen discovery expands the cancer immunopeptidome”

2018 Travel Awards

Each year, CIMT selects young scientists for travel awards of up to 1,000 EUR plus free conference admission to offset meeting-related expenses. Travel stipends are only awarded to scientists who have submitted an abstract to the Annual Meeting.

In 2018, CIMT awarded 17 travel awards.

Ioannis Morianos (Greece)

Rabia Bilge Özgül Özdemir (Turkey)

Alper Tunga Özdemir (Turkey)

Adanys Calvo Pérez (Cuba)

Elly Marcq (Belgium)

Efe Erdes (Switzerland)

Joao Oliveira Conniot (Portugal)

Carina Peres (Portugal)

Ana Matos (Portugal)

Christof Smith (USA)

Muzaffer Yildirim (Turkey)

Nur Ogan (Turkey)

Sofi Yado (Israel)

Mara de Martino (Argentina)

Judith Feucht (USA)

Dimitra Kerdidani (Greece)

Göksu Gökberk Kaya (Turkey)

CIMT | CIMT Immunoguiding Program (CIP)CIMT | CIMT Immunoguiding Program (CIP)

1110

Günter J. Hämmerling German Cancer Research Center DKFZ Dimitrios Mastellos National Center for Scientific Research ‘Demokritos’Nicholas McGranahan Cancer Research UK Lung Cancer Centre of Excellence

In addition, CIP was a partner of the EU-founded consortium GAPVAC (Glioma Actively Personalized Vaccine Consortium) within the 7th Framework Programme. For GAPVAC, CIP coordinated the development of a harmonized protocol for tumor-infiltrated lymphocyte (TIL) expansion from glioma tissues. The trial report was published in Nature at the beginning of 2019. (Hilf et al Nature 2019).

CIP is currently looking for new projects to advance immunoguiding and is inviting its members to provide input on what topic(s) CIP should address in their effort to harmonize (novel) immune monitoring assay(s).

Immunoguiding

The company Immudex in Copenhagen, Denmark organized a service panel for HLA-multimer staining to enumerate antigen-specific T cells by flow cytometry analysis in October/November 2018. 18 laboratories from 8 countries participated in the MHC Multimer Proficiency Panel 2018. The proficiency panel services offered by Immudex are open to any laboratory, independent of geographic location or field of interest, with a need to perform accurate and reproducible quantification of antigen-specific T cells.

The report which was published in January of 2019 provides individual test results for each participating laboratory, as well as an anonymized overview of the other participants’ test results. The report can be downloaded on the websites of CIP and Immudex.

Immudex continues the MHC Multimer and Elispot proficiency panels initiated by the Cancer Immunotherapy Consortium of the Cancer Research Institute and the CIMT Cancer Immunoguiding Program (CIP).

Outsourced projects

Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay. Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, Ottensmeier CH, Gouttefangeas C. Cytometry B Clin Cytom. 2018 Mar;94(2):342-353. (doi: 10.1002/cyto.b.21397).

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH. J Immunol Methods. 2018 Jul;458:74-82. (doi: 10.1016/j.jim.2018.04.007).

Actively personalized vaccination trial for newly diagnosed glioblastoma. Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Nature. 2019 Jan;565(7738):240-245. (doi: 10.1038/s41586-018-0810-y)

CIP publications and publications with collaborators 2018

With the financial support of its members, CIP was able to invite speakers for the immunoguiding session at the CIMT 2018 Annual Meeting. This support also helped to maintain the homepages of CIP and the MIATA program.

CIMT Immunoguiding Program (CIP)

CIMT | CIMT Regulatory Research Group (RRG) CIMT | CIMT Regulatory Research Group (RRG)

1312

CIMT Regulatory Research Group (RRG)

In the second half of 2018, the CIMT Regulatory Research Group (RRG) decided to reconstitute. The group will be led by Dr. Harpreet Singh and Dr. Thomas Hinz co-chairing the CIMT RRG. The three areas CIMT RRG will focus on are

1. Commenting and contributing to novel regulatory guidance in the field of cancer immunotherapy. As in the past, the RRG will also – where feasible – collaborate with the regulatory research groups of other international societies.

2. Educating the scientific community of the latest regulatory considerations in cancer immunotherapy. At the upcoming CIMT Annual Meeting in May 2019, CIMT RRG will arrange a dedicated Regulatory Session featuring the latest scientific development and regulatory considerations in the field of actively personalized cancer immunotherapy.

3. Conducting regulatory research focused on one or two major themes of interest to the scientific and regulatory community with a substantial unmet need.

For 2019 and 2020, CIMT RRG will focus on one or two themes. The first chosen focus theme will be considerations for developing pathways to commercialize actively personalized immunotherapies. This theme is the result of the successful work conducted by CIMT RRG five years ago on the concepts of actively personalized vaccines and published in Nature Biotechnology in 2013. Also based on this work, several clinical trials in this field have been successfully conducted, and a number of product candidates of this new class are further pursued with the goal to commercialize. Such actively personalized immunotherapies are a completely new treatment paradigm with an unchartered pathway to registration. CIMT RRG will attempt to contribute drafting possible pathways in collaboration with academia, regulators and biopharma companies.

In 2018, CIMT RRG organized a session at the CIMT Annual Meeting, exploring regulatory considerations of CAR T-cell therapies and products. The session was organized in collaboration with CARAT Consortium, a CAR T-cell network funded by the European Union’s Horizon 2020 research and innovation program. Martina Schüßler-Lenz, European Medicines Agency „Chimeric antigen receptor (CAR) modified T cells - EU regulatory considerations“ Martin Hildebrandt, Technical University Munich „From Karl Landsteiner to CAR-T cells: from processes to products and patients“ Bernd Schröder, Miltenyi Biotech „Translation of CAR-based innovations into clinics: how to overcome the regulatory hurdles”

CIMT | Fourth International CRI-CIMT-EATI-AACR Cancer Immunotherapy ConferenceCIMT | Fourth International CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

1514

Fourth International CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

After the great success of the joint Cancer Immunotherapy Conference hosted by CIMT in 2017 in Mainz, Germany, the meeting returned to New York City in September 2018.

CICON18 offered a four-day scientific program featuring talks from more than 50 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: regulating T cells and their response to cancer, tumor microenvironment, genetically engineered T cells, maintenance of immune balance, novel vaccine platforms and combinations, mutational analysis and predicting response to immunotherapy, convergence of technology and cancer immunotherapy, microbiome, and metabolism.

The highlight of the meeting was a surprise visit by James P. Allison on the day he had been named a recipient of the 2018 Nobel Prize in Physiology or Medicine. Dr. Allison, of the University of Texas MD Anderson Cancer Center, received the award along with Dr. Tasuku Honjo, of the University of Kyoto, “for their discovery of cancer therapy by inhibition of negative immune regulation”, according to a press release issued by the Nobel Foundation. This honor from the Nobel Foundation recognizing the potential of immunotherapy to transform treatment of all cancers validates the entire field and innovative work of its scientists.

Dr. Allison, recipient of the 2018 Nobel Prize in Physiology or Medicine along with Dr. Tasuku Honjo.

CIMT | Financial SummaryCIMT | Meeting Statistics

1716

Balance as of December 31, 2018

Financial SummaryMeeting Statistics

ASSETS 2018 2017

Fixed Assets € 6,228 € 56,760

Current Assets € 83,405 € 202,129

Banks € 695,897 € 623,401

€ 785,530 € 882,290

LIABILITIES 2018 2017

Equity € 705,953 € 821,275

Accruals € 62,800 € 46,243

Liabilities € 16,777 € 14,772

€ 785,530 € 882,290

2018 2017

Turnover € 484,547 € 1,025,126

Other Income incl. donation € 46,567 € 142,296

Personnel expenses € -87,579 € -87,723

Depreciation € 1,760 € -2,456

Expenses for CIMT meetings € -357,411 € -646,496

Other expenses € -170,274 € -197,750

Income taxes € -33,002 € -54,645

€ -115,392 € 178,3522012 2013 2014 2015 2016 2017 2018

2012CIMT Annual Meeting

667 participantsTowards Next-Generation Cancer Immunotherapy

2014CIMT Annual Meeting

996 participantsNext Waves inCancer Immunotherapy

2016CIMT Annual Meeting

931 participantsMechanisms of Effiancy in Cancer Immunotherapy

2013CIMT Annual Meeting

755 participantsAdvancing Targeted Therapies

2018CIMT Annual Meeting

750 participantsPushing frontiers in cancer immunotherapy

2015CIMT Annual Meeting

887 participantsThe right patientfor the right therapy

CIMT Anniversary Symposium

184 participants

2017International CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference

1460 participants

CIMT Addresses / Imprint

18

© Association for Cancer Immunotherapy CIMT e.V. All rights reserved.

POSTAL ADDRESS

Association for Cancer Immunotherapy CIMT e.V.

Hölderlinstraße 8

55131 Mainz, Germany

Telephone: +49 (0) 6131 - 55 47 40 0

Website: www.cimt.eu

E-Mail: office@cimt.eu

REGISTER OF ASSOCIATIONS

Amtsgericht Mainz: VR 3783

CONCEPT AND DESIGN

LABOR − Agentur für moderne Kommunikation GmbH

Fischtorplatz 21

55116 Mainz, Germany

Telephone: +49 (0) 6131 - 30 46 76 2

Website: www.labor.digital

TEXTS AND EDITING

Christine Castle

Christiane Wellié-Reeve

PHOTOS

Andrea Enderlein

Cancer Research Institute

Addresses / Imprint

follow us on twitter www.twitter.com/C_IMT

follow us on Linkedin www.linkedin.com/company/cimt

find us on facebook www.facebook.com/cimtmainz